FACILITIES CONSTRUCTION CENTERALIZED PHARMCOGENOMICS

设施建设集中化药物基因组学

• 批准号: 6720427
• 负责人: PALMER William TAYLOR
• 金额: $ 336.96万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-15 至 2005-09-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6720427
• 关键词: Rodentias; animal colony; biomedical facility; building /facility design /renovation; cardiovascular disorder; gene expression; pharmacogenetics; pharmacology

DESCRIPTION (provided by applicant): In this rewritten and resubmitted application, funds are requested to match State of California funds for an 8,059 ASF Centralized Pharmacogenomics and Toxicogenomics Animal Facility in a new pharmaceutical sciences building. The building will house collaborating investigators from the School of Medicine and School of Pharmacy and Pharmaceutical Sciences (SPPS). UCSD has traditionally strength in genetics, but only recently have large research programs in the form of program projects and centers come to the forefront. Appropriately, this has coincided with the emergence of the genomic era. The proposed new facility will enable established and newly recruited faculty to conduct cornerstone studies in pharmacogenomics, toxicogenomics and disease-related genomics. These areas of research are a top priority in UCSD Health Sciences. In particular, centers and program projects in ischemic heart disease, myocardial development, signaling in hypertension and genetics of hypertension, along with individual projects in genetic models of disease require increased and specialized animal facilities. Two newly funded NIH centers, in Pharmacogenomics-"Autonomic Pharmacodynamic Pharmacogenomics" and "Toxicogenomics Molecular Mechanisms and Models for Exposure", are creating great demand for facilities to create, house, and study genetically altered rodents. Both pharmacogenomics and toxicogenomics represent cutting edge areas for research in the pharmaceutical sciences. Efficacy, selection and dosing of drugs will depend on genomic information such as single nucleotide polymorphisms in the germ line and nucleotide insertions and chromosomal rearrangements in neoplastic or proliferative diseases. In toxicogenomics, examining alterations in gene expression upon exposure to environmental toxicants, represents a novel approach to assessing exposure risks and consequences. Selection of lead agents in structure-guided drug development depends on eliminating potential toxicity patterns through gene expression screens. The new building will have coordinated research conducted in these three intimately related and well-defined areas. The Centralized Animal Facility is critically needed to support this effort and allow economies of scale for animal research.

描述（由申请人提供）： 在此重写和重新提交的应用中，要求资金与新的药物科学大楼中的8,059 ASF集中药物基因组学和毒理基因组学动物设施相匹配。 该建筑物将容纳医学院和药学科学学院（SPPS）的调查人员。 UCSD传统上具有遗传学的力量，但直到最近才有大型的研究计划，以计划项目和中心的形式出现。 适当地，这与基因组时代的出现相吻合。 拟议的新设施将使已建立和新招募的教师能够在药物基因组学，毒理基因组学和与疾病相关的基因组学方面进行基石研究。 这些研究领域是UCSD健康科学的重中之重。 特别是，缺血性心脏病，心肌发育，高血压和高血压遗传学的信号以及疾病遗传模型中的个别项目需要增加和专业的动物设施。 两个新资助的NIH中心，用于药物基因组学 - “自主药物学药物学药物基因组学”和“有毒基因组学分子机制和暴露模型”，正在为创建，房屋和研究遗传改变的啮齿动物的设施创造巨大的需求。 药物基因组学和毒物基因组学都代表了药物研究中的尖端领域。 药物的疗效，选择和给药将取决于基因组信息，例如生殖系中的单核苷酸多态性以及肿瘤或增殖性疾病中的核苷酸插入以及染色体重排。 在毒物基因组学中，检查暴露于环境毒物后基因表达的改变，是一种评估暴露风险和后果的新方法。 在结构引导的药物开发中的选择取决于通过基因表达筛选消除潜在的毒性模式。 新建筑将在这三个密切相关且定义明确的地区进行协调研究。 需要至关重要的动物设施来支持这一努力，并允许动物研究规模经济。